Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
NOVARTIS AG
Bear Case (25th pct.)
22.0% vs price
Base Case (Median)
78.8% vs price
Bull Case (75th pct.)
133.7% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $242.23 | 174.2% | High (40%) |
| PE Comparable | $157.99 | 78.8% | Medium (25%) |
| Growth Trajectory DCF | $239.04 | 170.6% | Medium (20%) |
| Graham Number | $62.41 | -29.3% | Medium (40%) |
| EV/EBITDA | $86.06 | -2.6% | Medium (20%) |
| EV/FCF | $173.87 | 96.8% | Medium (20%) |
| Earnings Power Value | $129.54 | 46.6% | Medium (50%) |
Based on 7 out of 7 methods, NVSEF appears undervalued at the current price of $88.34. The base case fair value of $157.99 implies 78.8% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.